|1.||Zhou, Jin: 8 articles (05/2011 - 11/2003)|
|2.||Platanias, Leonidas C: 6 articles (10/2012 - 11/2006)|
|3.||Chen, Zhu: 6 articles (02/2005 - 11/2002)|
|4.||Altman, Jessica K: 5 articles (10/2012 - 01/2008)|
|5.||Tallman, Martin S: 5 articles (11/2010 - 11/2006)|
|6.||Meng, Ran: 5 articles (01/2010 - 11/2003)|
|7.||Waxman, Samuel: 5 articles (08/2008 - 04/2003)|
|8.||Hirano, Toshihiko: 4 articles (12/2011 - 02/2003)|
|9.||Tang, Xueming: 4 articles (06/2006 - 01/2002)|
|10.||Yi, Jing: 4 articles (06/2006 - 01/2002)|
|1.||Acute Promyelocytic Leukemia
06/15/2003 - "Although parenteral administration of As(2)O(3) is highly effective in the treatment of acute promyelocytic leukemia, cardiac toxicity has been reported. "
09/15/1999 - "Low concentrations of As(2)O(3) (</=1 micromol/L) induce long-lasting remission in patients with acute promyelocytic leukemia (APL) without significant myelosuppressive side effects. "
07/13/2010 - "As(2)O(3) cures acute promyelocytic leukemia (APL) by initiating PML/RARA oncoprotein degradation, through sumoylation of its PML moiety. "
12/01/2007 - "Differentiation Syndrome (DS) is a treatment complication which can occur in patients treated with acute promyelocytic leukemia (APL) with all transretinoic acid (ATRA) or As(2)O(3), and is characterized by enhanced leukocyte transmigration. "
04/01/2004 - "As trioxide (As(2)0(3)) has been recently used as a mitochondria-targeting drug in acute promyelocytic leukemia. "
10/14/2000 - "Although tumor growth was reduced by As(2)O(3) treatment, complete remission was not achieved at the concentrations tested. "
06/01/1981 - "We have previously described a passive serum therapy system in which potent protection against challenge of syngeneic mice with large doses (10(4) X LD100) of AD755a tumor cells can be accomplished by administration of as little as 2 to 5 microliters/mouse of hyperimmune anti-tumor cell serum. "
04/01/2012 - "A significant reduction of 37 ± 13% in tumor perfusion and microvessel permeability (measured by K (trans)) was observed as early as 2 h after administration compared with vehicle treatment. "
12/15/2011 - "Thus, the systematic study of the combination of As(2)O(3) with other clinically used chemotherapeutic drugs to improve its therapeutic efficacy in treating human solid tumors is merited. "
12/15/2011 - "After the discovery of As(2)O(3) as a promising treatment for APL, several studies investigated the use of As(2)O(3) as a single agent in the treatment of solid tumors; however, its therapeutic efficacy is limited. "
06/15/2003 - "Our data provide the first evidence that DHA may help to extend the therapeutic spectrum of As(2)O(3) and suggest that the combination of As(2)O(3) and DHA could be more broadly applied in leukemia therapy."
09/01/2012 - "In this study, we provided in vitro evidence that As(2)O(3) was a potent inducer of autophagy in leukemia K562 and its drug-resistant line K562/ADM cells. "
05/15/2009 - "The present study aimed at investigating the enhanced effects and mechanisms in cell cycle distribution and apoptosis of U937 cells, a human pre-monocytic leukemia cell line lacking functional p53 protein, after combination treatment with irradiation and As(2)O(3). "
09/01/2005 - "Although a number of studies have demonstrated that As(2)O(3) has potent activity against cell growth in a series of leukemia cell lines, little information is available regarding this compound's effect on cell growth in solid tumor cell lines. "
09/01/2012 - "The expression level of Bcl-2 gene, an anti-apoptotic molecule, decreased in As(2)O(3) treated samples than in controls, suggesting that Bcl-2 may be involved in accumulating Beclin-1 and triggering autophagic cell death in As(2)O(3)-treated leukemia cells. "
03/01/1993 - "Snails exposed to infection when immature, even in the group where no patent development ensued, showed a statistically significant reduction in growth and this was evident as early as 2-5 weeks post exposure. "
01/01/2013 - "In this study, we show that infection of mice with Lymphocytic Choriomeningitis Virus WE (LCMV WE) leads to increased plasma levels of FGL2, which were detected as early as 2 days post-infection (pi) and persisted until day 50 pi. "
12/01/2009 - "Proviral load analysis indicated that rabbits with higher proviral loads had significant CTL activity against HTLV-1 SU as early as 2 wk post-infection, while both low- and high-proviral-load groups had minimal Tax-specific CTL activity throughout the study. "
04/01/2004 - "Ultrastructural studies showed that internalized yeasts were found inside endocytic vacuoles as early as 2 h, without causing any detectable damage to HUVECs after 24 h of infection. "
01/01/1995 - "A first trial with experimentally infected heifers showed an increase in anti-fluke antibody titre as early as 2 weeks post-infection. "
10/01/2008 - "This study provides a new thought and direction for exploring possible mechanism of cell apoptosis induced by As(2)O(3) and multiple myeloma treatment by As(2)O(3)."
04/07/2011 - "In multiple myeloma (MM) pathogenesis, hyperdiploidy and nonhyperdiploidy are recognized as 2 major cytogenetic pathways. "
02/12/2004 - "Here, we show that clinically relevant doses of As(2)O(3) can induce typical apoptosis in IM-9, a multiple myeloma cell line, in a Bcl-2 inhibitable manner. "
07/01/2010 - "As(2)O(3) has also shown efficacy in other malignancies, particularly multiple myeloma and myelodysplastic syndromes. "
01/01/2012 - "Arsenic trioxide (As(2)O(3)) has shown remarkable efficacy for the treatment of multiple myeloma (MM). "
|1.||arsenic trioxide (Trisenox)
|2.||Tretinoin (Retinoic Acid)
|4.||Arsenicals (Arsenic Compounds)
|7.||promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
|8.||Messenger RNA (mRNA)
|9.||Aspirin (Acetylsalicylic Acid)
|10.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|5.||Renal Dialysis (Hemodialysis)